These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11092617)

  • 1. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.
    Hörig H; Lee DS; Conkright W; Divito J; Hasson H; LaMare M; Rivera A; Park D; Tine J; Guito K; Tsang KW; Schlom J; Kaufman HL
    Cancer Immunol Immunother; 2000 Nov; 49(9):504-14. PubMed ID: 11092617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
    von Mehren M; Arlen P; Tsang KY; Rogatko A; Meropol N; Cooper HS; Davey M; McLaughlin S; Schlom J; Weiner LM
    Clin Cancer Res; 2000 Jun; 6(6):2219-28. PubMed ID: 10873071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
    Arlen P; Tsang KY; Marshall JL; Chen A; Steinberg SM; Poole D; Hand PH; Schlom J; Hamilton JM
    Cancer Immunol Immunother; 2000 Dec; 49(10):517-29. PubMed ID: 11129322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
    Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.
    Marshall JL; Hawkins MJ; Tsang KY; Richmond E; Pedicano JE; Zhu MZ; Schlom J
    J Clin Oncol; 1999 Jan; 17(1):332-7. PubMed ID: 10458251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
    Marshall JL; Hoyer RJ; Toomey MA; Faraguna K; Chang P; Richmond E; Pedicano JE; Gehan E; Peck RA; Arlen P; Tsang KY; Schlom J
    J Clin Oncol; 2000 Dec; 18(23):3964-73. PubMed ID: 11099326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
    Hodge JW; McLaughlin JP; Kantor JA; Schlom J
    Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
    Bilusic M; Heery CR; Arlen PM; Rauckhorst M; Apelian D; Tsang KY; Tucker JA; Jochems C; Schlom J; Gulley JL; Madan RA
    Cancer Immunol Immunother; 2014 Mar; 63(3):225-34. PubMed ID: 24327292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
    Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
    Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
    Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
    J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
    Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
    Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
    Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
    Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
    Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
    Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.
    Zhu MZ; Marshall J; Cole D; Schlom J; Tsang KY
    Clin Cancer Res; 2000 Jan; 6(1):24-33. PubMed ID: 10656428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
    Hodge JW; McLaughlin JP; Abrams SI; Shupert WL; Schlom J; Kantor JA
    Cancer Res; 1995 Aug; 55(16):3598-603. PubMed ID: 7543017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
    Kaufman HL; Lenz HJ; Marshall J; Singh D; Garett C; Cripps C; Moore M; von Mehren M; Dalfen R; Heim WJ; Conry RM; Urba WJ; Benson AB; Yu M; Caterini J; Kim-Schulze S; Debenedette M; Salha D; Vogel T; Elias I; Berinstein NL
    Clin Cancer Res; 2008 Aug; 14(15):4843-9. PubMed ID: 18676757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.